203866-15-3

Basic information

• Product Name: N-BOC-4,4-difluoro-L-proline
• Synonyms: BOC-4,4-DIFLUORO-L-PROLINE;BOC-L-PRO(4,4-DIFLUORO);N-BOC-4,4-DIFLUORO-L-PROLINE;N-T-BOC-4,4-DIFLUORO-L-PROLINE;(2S)-Boc-4,4-difluoro-pyrrolidine-2-carboxylic acid;(S)-1-(tert-Butoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylic acid;N-Boc-4,4-difluoro-L-proline, 97+%;(S)-1-Boc-4,4-difluoropyrrolidine-2-carboxylic acid
• CAS NO: 203866-15-3
• Molecular Formula: C₁₀H₁₅F₂NO₄
• Molecular Weight: 251.23
• Product Categories: Chiral Building Blocks;Heterocyclic Building Blocks;Pyrrolidines
• Mol File: 203866-15-3.mol
• Article Data: 22

Chemical Properties

• Melting Point: 120-124°C
• Boiling Point: 340.386 °C at 760 mmHg
• Flash Point: 159.66 °C
• Appearance: /
• Density: 1.312 g/cm³
• Vapor Pressure: 1.58E-05mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: Store at 0-5°C
• PKA: 3.06±0.40(Predicted)
• CAS DataBase Reference: N-BOC-4,4-difluoro-L-proline(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4,4-difluoro-L-proline(203866-15-3)
• EPA Substance Registry System: N-BOC-4,4-difluoro-L-proline(203866-15-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 203866-15-3(Hazardous Substances Data)

Usage

Chemical Properties

solid

Uses

N-Boc-4,4-difluoro-L-proline is a reagent used in the preparation of structure-activity relationship and pharmacokinetics of pyrrolotriazines as pan-Aurora kinase inhibitors and anti tumor agents.

InChI:InChI=1/C10H15F2NO4/c1-9(2,3)17-8(16)13-5-10(11,12)4-6(13)7(14)15/h6H,4-5H2,1-3H3,(H,14,15)/t6-/m0/s1

Upstream product

• 89813-47-8 N-(tert-butoxycarbonyl)-(2S,4R)-4-hydroxyproline benzyl ester 
• 154456-97-0 2-benzyl 1-(tert-butyl) (S)-4-oxopyrrolidine-1,2-dicarboxylate 
• 796095-60-8 (2S)-1-tert-butoxycarbonyl-2-(methoxycarbonyl)-4-hydroxyazacyclopentane 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 

Downstream Products

• 52683-81-5 (S)-4,4-difluoro-pyrrolidine-2-carboxylic acid 
• 681128-16-5 1-(tert-butoxycarbonyl)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-4,4-difluoro-L-prolinamide 
• 911831-66-8 Boc-N-[5-chloro-2-(1H-1,2,4-triazol-1-yl)benzyl]-4,4-difluoro-L-prolinamide 
• 215918-21-1 (S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 681128-24-5 [(R)-2-[(S)-2-(5-Chloro-2-tetrazol-1-yl-benzylcarbamoyl)-4,4-difluoro-pyrrolidin-1-yl]-1-(1-methyl-cyclopropylmethyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 1447943-90-9 (rac)-4,4-difluoro-2-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1337389-01-1 C₂₁H₂₅F₂NO₂Si 
• 1448440-48-9 (S)-tert-butyl 2-(2-carbamoyl-4,4-difluoropyrrolidin-1-yl)-2-oxoethylcarbamate 
• 1448440-50-3 tert-butyl (S)-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)carbamate 
• 1448440-51-4 (S)-1-(2-aminoacetyl)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride 
• 426844-50-0 (S)-2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylic acid tert-butyl ester 
• 1315625-40-1 C₁₆H₂₀BrF₂N₃O₃ 
• 1250940-53-4 C₃₈H₄₂F₄N₄O₈ 

Relevant articles and documents

ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES

The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.